X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ADCOCK INGRAM
Jun-14
TORRENT PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,768404-   
Low Rs1,186291-   
Sales per share (Unadj.) Rs346.1120.1-  
Earnings per share (Unadj.) Rs55.2-30.3-  
Cash flow per share (Unadj.) Rs73.3-25.1-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs257.194.3-  
Shares outstanding (eoy) m169.22168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.32.9 147.5%   
Avg P/E ratio x26.8-11.5 -233.1%  
P/CF ratio (eoy) x20.1-13.9 -145.4%  
Price / Book Value ratio x5.73.7 155.8%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m249,88758,663 426.0%   
No. of employees `00011.84.3 274.4%   
Total wages/salary Rs m9,9343,682 269.8%   
Avg. sales/employee Rs Th4,971.54,722.8 105.3%   
Avg. wages/employee Rs Th843.2857.6 98.3%   
Avg. net profit/employee Rs Th792.4-1,190.0 -66.6%   
INCOME DATA
Net Sales Rs m58,56920,275 288.9%  
Other income Rs m2,233142 1,572.8%   
Total revenues Rs m60,80220,417 297.8%   
Gross profit Rs m13,773-3,514 -392.0%  
Depreciation Rs m3,069875 350.7%   
Interest Rs m2,056549 374.3%   
Profit before tax Rs m10,881-4,796 -226.9%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545300 515.6%   
Profit after tax Rs m9,336-5,109 -182.7%  
Gross profit margin %23.5-17.3 -135.7%  
Effective tax rate %14.2-6.2 -227.3%   
Net profit margin %15.9-25.2 -63.3%  
BALANCE SHEET DATA
Current assets Rs m53,84114,850 362.6%   
Current liabilities Rs m31,6128,355 378.4%   
Net working cap to sales %38.032.0 118.5%  
Current ratio x1.71.8 95.8%  
Inventory Days Days97111 87.6%  
Debtors Days Days84124 67.6%  
Net fixed assets Rs m42,0798,656 486.1%   
Share capital Rs m84694 898.9%   
"Free" reserves Rs m42,6550-   
Net worth Rs m43,50115,913 273.4%   
Long term debt Rs m22,4085,592 400.7%   
Total assets Rs m101,25030,062 336.8%  
Interest coverage x6.3-7.7 -81.4%   
Debt to equity ratio x0.50.4 146.6%  
Sales to assets ratio x0.60.7 85.8%   
Return on assets %11.3-15.2 -74.2%  
Return on equity %21.5-32.1 -66.8%  
Return on capital %19.6-19.8 -99.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m14,7620-   
CASH FLOW
From Operations Rs m10,1271,731 585.2%  
From Investments Rs m-7,869-531 1,480.9%  
From Financial Activity Rs m-1,9185,075 -37.8%  
Net Cashflow Rs m2126,275 3.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.57 Rs / ZAR

Compare TORRENT PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: GSK PHARMA  FRESENIUS KABI ONCO.  DR. DATSONS LABS  FDC LTD.  LUPIN LTD  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - WYETH LTD COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS